Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling.

The current level of evidence for immunotherapy in previously untreated microsatellite unstable metastatic colorectal cancer is based on recent pieces of evidence of few studies that demonstrated durable response and clinical benefit, in terms of objective response rate, disease control rate, and progression-free survival in this subgroup of patients. On the basis of combinatorial immunotherapy with nivolumab plus ipilimumab, we report the exceptional case of a complete pathological response in a 21-year-old woman presenting a clinically aggressive stage IV colorectal cancer with massive nodal and liver involvement. Extensive molecular analyses based on whole genome next-generation DNA sequencing, RNA sequencing, fluorescent multiplex immunohistochemistry, and flow cytometry provided a detailed description of tumoral and immunological characteristics of this noteworthy clinical case.

Informations de copyright

Copyright © 2022 Bergamo, Dalla Santa, Loupakis, Cerma, Tosi, De Grandis, Dalla Pietà, Gringeri, Angerilli, Ramondo, Rago, Cecchi, Benz, Cillo, Dei Tos, Zagonel, Fassan, Rosato and Lonardi.

Déclaration de conflit d'intérêts

VZ declares a conflict of interest: consulting or Advisory Role: Bristol-Myers Squibb, MSD, Eisai, ITALFARMACO; Speakers Bureau: Roche, Bristol-Myers Squibb, Astellas Pharma, SERVIER, AstraZeneca, MSD, JANSEN, IPSEN; Research Funding: Bayer, Roche, Lilly, Astra Zeneca, BMS, Ipsen, Astellas Pharma. SL reports personal fees as speaker bureau or advisor from Amgen, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, MSD, Roche, Bristol-Myers Squibb, Pierre-Fabre, GSK and received research grants from Amgen, Merck Serono, Bayer, Roche, Lilly, Astra Zeneca, Bristol-Myers Squibb, unrelated to the current work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.